Depleting FOXP3 (hi) Treg cells from tumor tissues could be deployed to increase the antitumor immunity to treat CRC or other cancers, whereas other strategies enhancing the levels of FOXP3(lo) non-Treg T cells could also be used to suppress or prevent tumorigenesis [96]. This evidence concerns the gene FOXP3 and cancer.